Fig 1: The expression of IGFBPs in ovarian cancer. (A) The mRNA expression in six ovarian cancer tissues and five normal ovarian tissues. The relative protein expression of IGFBP2 (B), IGFBP3 (C), IGFBP4 (D), IGFBP5 (E), and IGFBP6 (F) in ovarian cancer. The red and blue boxes represent tumor tissues and normal tissues, respectively. *p < 0.05, **p < 0.01, ***p < 0.001.
Fig 2: The relationship between the expression of IGFBPs and TMB. (A–F) The radar map displaying the correlation of TMB with IGFBP1 (A), IGFBP2 (B), IGFBP3 (C), IGFBP4 (D), IGFBP5 (E), and IGFBP6 (F). *p < 0.05, **p < 0.01, ***p < 0.001. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; DLBC, diffuse large B cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.
Fig 3: Effects of IGFBP5 on invasion and migration of ovarian cancer cells. (A) The expression of IGFBP5 in two risk groups. (B) The levels of tumor biological pathways in two risk groups. (C) Representative EMT markers were assayed by western blot. (D) A transwell invasion assay was performed to evaluate the invasion ability of SKOV3 without or with IGFBP5 recombinant protein (5 ng/mL) for 24 h. (E) A wound healing assay was performed to evaluate the migration ability of SKOV3 without or with IGFBP5 recombinant protein (5 ng/mL) for 24 h. *p < 0.05, **p < 0.01, ***p < 0.001. ns means no statistic difference.
Fig 4: The expression of IGFBPs in pan‐cancer. (A–F) The expression level of IGFBP1 (A), IGFBP2 (B), IGFBP3 (C), IGFBP4 (D), IGFBP5 (E), and IGFBP6 (F) were compared based on the integrated database from TCGA and GTEx. The red and blue boxes represent tumor tissues and normal tissues respectively. *p < 0.05, **p < 0.01, ***p < 0.001. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma; CHOL, cholangiocarcinoma; COAD, colon adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; READ, rectum adenocarcinoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; THCA, thyroid carcinoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma.
Fig 5: The prognostic of IGFBPs in GSE26712. (A) Univariate Cox analysis of IGFBPs in ovarian cancer. (B–E) The survival analysis of IGFBP3 (B), IGFBP4 (C), IGFBP5 (D), and IGFBP6 (E). (F) Multivariate Cox analysis of IGFBPs.
Supplier Page from MedChemExpress for IGFBP-5 Protein, Human (HEK293, His)